MaxCyte, Inc. (MXCT) company profile

MaxCyte is a commercial cell engineering company that provides enabling platform technologies for cell therapeutics and cell-based research and development. Its primary offering is the proprietary ExPERT platform, which utilizes Flow Electroporation technology to deliver diverse molecules into eukaryotic cells. The ExPERT product family comprises five benchtop instruments—the DTx, ATx, STx, GTx, and VLx—along with specialized disposables such as processing assemblies, consumables like electroporation buffers, and software protocols. The company also provides gene editing assessment services through its SeQure Dx business. MaxCyte serves commercial cell therapy drug developers, biopharmaceutical corporations, academic centers, and government research bodies such as the U.S. National Institutes of Health.

The company operates globally through commercial and field application scientist teams that support customer programs across research, clinical, and commercial phases. MaxCyte maintains an intellectual property portfolio of more than 200 granted patents worldwide and had 91 full-time employees as of year-end 2025. The provided text does not identify its corporate headquarters.

Summary of the business section of MaxCyte's latest annual report, written by StockData.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“We are offering 13,500,000 shares of our common stock at a public offering price of $13.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

“As of December 31, 2025, we had 91 full-time employees which is inclusive of individuals employed through third-party employer-of-record (“EOR”) employees , 50 of whom have advanced degrees, including 23 with Ph.D.”